ASM Technologies (526433) Q2 23/24 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 23/24 earnings summary
16 Oct, 2026Executive summary
Standalone Q2 FY23 total income rose to ₹391.37 mn from ₹337.98 mn YoY, while consolidated total income fell to ₹507.85 mn from ₹649.96 mn.
Consolidated results included a ₹27.49 mn net loss; guidance cited scaling new customers, revenue from completed trials, and the Semcon UK acquisition as a future contributor.
Financial highlights
Standalone Q2 FY23 revenue was ₹391.37 mn, EBITDA ₹36.55 mn, and PAT ₹30.71 mn, versus ₹337.98 mn, ₹58.43 mn, and ₹3.11 mn, respectively, in Q2 FY22.
Consolidated Q2 FY23 revenue was ₹507.85 mn, EBITDA ₹23.24 mn, and PAT -₹27.49 mn, versus ₹649.96 mn, ₹76.50 mn, and ₹24.81 mn in Q2 FY22.
H1 FY23 total income was ₹659.33 mn standalone and ₹1,037.17 mn consolidated; PAT was ₹4.71 mn and -₹29.67 mn, respectively.
Outlook and guidance
New customers are beginning to scale, and completed trials are expected to start generating revenue.
The Semcon UK Engineering acquisition was expected to be accretive.
Latest events from ASM Technologies
- Q1 FY25 profit improved, while overseas subsidiary losses remained a key risk.526433
Q1 24/25 - H1 profits recovered, while cash outflow and overseas subsidiary losses remain key risks.526433
Q2 24/25 - Q3 profit recovery and dividend declaration offset by overseas subsidiary losses.526433
Q3 24/25 - Q1 FY27 revenue and profit rose year over year; interim dividend declared at ₹6 per share.526433
Q1 26/27 - FY25 growth and return to consolidated profit, alongside overseas subsidiary net-worth risks.526433
Q4 24/25 - Q1 revenue and profit surged as a ₹510 cr Karnataka capacity investment was proposed.526433
Q1 25/26 - Q2 revenue grew 171% as ~₹760 Cr of capacity investments were planned.526433
Q2 25/26 - 9M revenue and profit surged as expansion advanced; overseas subsidiary risks persist.526433
Q3 25/26 - FY26 revenue grew 83% as earnings strengthened and manufacturing capacity expanded.526433
Q4 25/26